Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis

ABSTRACT Background Obesity represents a major global health challenge, contributing substantially to cardiovascular disease and metabolic complications. Orforglipron, a novel oral non‐peptide GLP‐1 receptor agonist, has emerged as a promising therapeutic option for weight management and glycemic co...

Descripció completa

Dades bibliogràfiques

Autors principals:	Ravi Kumar Pandey, Mahnoor Jan, Aqsa Mohammad, Khawaja Arham Jawaid, Mawra Naveed, Muhammad Ali Abid, Abdullah Bin Amir, Shafique Ahmed, Muhammad Safiullah, Muhammad Imaz Bhatti, Sana Iftikhar, Muhammad Nabeel Saddique, Widyan Alfalh, Rihab Mohammed bin Omar, Husam Abu Dawood
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2025-11-01
Col·lecció:	Endocrinology, Diabetes & Metabolism
Matèries:	GLP‐1 receptor agonist glycemic control meta‐analysis obesity orforglipron type 2 diabetes mellitus
Accés en línia:	https://doi.org/10.1002/edm2.70134
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!